News - Merck Serono, Regulation


Current filters:

Merck SeronoRegulation

Popular Filters

European Commission backs wider use of Merck’s Erbitux

European Commission backs wider use of Merck’s Erbitux


Merck Serono, the biopharmaceutical division of Germany’s Merck KGaA, has gained European Commission…

ErbituxEuropeMerck KGaAMerck SeronoOncologyPharmaceuticalRegulation

Briefs: Takeda and Lundbeck file vortioxetine NDA; Merck Serono spin-out


Japan's biggest drugmaker Takeda Pharmaceutical (TYO: 4502) and partner Danish CNS specialist Lundbeck…

AsceneurionBiotechnologyLundbeckMerck KGaAMerck SeronoMergers & AcquisitionsNeurologicalPharmaceuticalRegulationTakeda Pharmaceuticalsvortioxetine

News briefs from Threshold, Merck KGaA and GSK


US biotech firm Threshold Pharmaceuticals (Nasdaq: THLD) said yesterday that data from a Phase IIb trial…

BiotechnologyErbituxEuropeGlaxoSmithKlineMerck KGaAMerck SeronoOncologyPharmaceuticalRegulationResearchSynflorixTH-302Threshold PharmaceuticalsVaccines

Expanded use for Merck Serono’s Rebif in EU


Merck Serono, the Switzerland-based division of Germany’s Merck KGaA (MRK: DE), says that that the…

EuropeMerck KGaAMerck SeronoNeurologicalPharmaceuticalRebifRegulation

UK NICE nixes three colorectal cancer drugs; gives nod to blood thinner Eliquis


In a batch of mixed news coming from the UK’s National Institute for Health and Clinical Excellence…

AmgenAvastinBristol-Myers SquibbCardio-vascularEliquisErbituxMerck & CoMerck SeronoOphthalmicsPfizerPharmaceuticalPricingRegulationRocheVectibix

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top